<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00293111</url>
  </required_header>
  <id_info>
    <org_study_id>SDX-101-04</org_study_id>
    <nct_id>NCT00293111</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)</brief_title>
  <official_title>An Open Label, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cephalon</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Branded Pharmaceutical Products R&amp;D, Inc.</source>
  <brief_summary>
    <textblock>
      An Open Label, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101&#xD;
      (R-Etodolac) in Patients with Relapsed or Refractory Multiple Myeloma (MM)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>February 2002</start_date>
  <primary_completion_date type="Actual">October 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>30</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SDX-101 (R-Etodolac)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Previously diagnosis of multiple myeloma as determined by any two of the major&#xD;
             criteria, or major criteria 1 plus minor criteria b, c, or d, or major criteria 3 plus&#xD;
             minor criteria a or c, or minor criteria a, b and c or a, b, and d.&#xD;
&#xD;
             Major criteria:&#xD;
&#xD;
               -  Plasmacytomas on tissue biopsy&#xD;
&#xD;
               -  Bone marrow plasmacytomas (&gt;30% plasma cells)&#xD;
&#xD;
               -  Monoclonal immunoglobulin spike on serum electrophoresis immunoglobulin G (IgG)&#xD;
                  &gt;3.5 g/dl or immunoglobulin A (IGA) &gt; 2.0 g/dl; kappa or lambda light chain&#xD;
                  excretion &gt; 1 g/day on 24 hour urine protein electrophoresis&#xD;
&#xD;
             Minor criteria:&#xD;
&#xD;
               1. Bone marrow plasmacytomas (10 to 30% plasma cells)&#xD;
&#xD;
               2. Monoclonal immunoglobulin present but of lesser magnitude than given under major&#xD;
                  criteria&#xD;
&#xD;
               3. Lytic bone lesions&#xD;
&#xD;
               4. Normal IgM &lt; 50 mg/dl, IgA &lt; 100 mg/dl, or IgG &lt; 600 mg/dl&#xD;
&#xD;
          2. Has relapsed or refractory disease as determined by the following:&#xD;
&#xD;
             Relapsed disease:&#xD;
&#xD;
             • Disease progression developed following the achievement of at least stable disease&#xD;
             or better to an anti-myeloma regimen.&#xD;
&#xD;
             Refractory disease:&#xD;
&#xD;
             • Disease progression developed during therapy with an anti-myeloma regimen prior to&#xD;
             the achievement of at least stable disease or better. Includes the development of&#xD;
             disease progression during maintenance or consolidation therapy with glucocorticoids&#xD;
             or cytotoxic chemotherapy.&#xD;
&#xD;
          3. Age &gt; 18 at signing of informed consent.&#xD;
&#xD;
          4. ECOG performance status 0-2.&#xD;
&#xD;
          5. Renal function 1.5 x upper limit normal (blood urea nitrogen [BUN], serum creatinine&#xD;
&#xD;
          6. Liver function ≤ 1.5 times upper limit of normal (total bilirubin, SGOT (AST) and SGPT&#xD;
             (ALT) values).&#xD;
&#xD;
          7. Female patients of childbearing potential must have a negative pregnancy test (serum&#xD;
             -human chorionic gonadotropin, -HCG); men and women of reproductive potential must&#xD;
             employ effective contraceptive methods while on study therapy, and for 1 month&#xD;
             following completion of treatment.&#xD;
&#xD;
          8. Signed IRB-approved informed consent by patient prior to all study related procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of a prior malignancy with in the last 3 years with the exception of resected&#xD;
             basal cell carcinoma, in situ cervical cancer at any time or other resected&#xD;
             malignancies with no evidence of recurrence 5 or more years since diagnosis.&#xD;
&#xD;
          2. Patients with a hemoglobin count of &lt; 8.0 g/dl, platelet count of &lt; 50,000 cells/mm3,&#xD;
             or an absolute neutrophil count (ANC) of &lt; 1000 cells/mm3.&#xD;
&#xD;
          3. Serious infection, medical condition, or psychiatric condition that, in the opinion of&#xD;
             the investigator, places the subject at unacceptable risk or might interfere with the&#xD;
             achievement of the study objectives.&#xD;
&#xD;
          4. Chronic viral infection: positive hepatitis B or hepatitis C serology, known positive&#xD;
             for human immunodeficiency virus (HIV) or human T-leukemia/lymphoma virus (HTLV).&#xD;
&#xD;
          5. Peptic ulcer disease (PUD) requiring treatment or surgical intervention within the&#xD;
             last 2 years.&#xD;
&#xD;
          6. The use of steroids or chronic nonsteroidal anti-inflammatory drugs 28 days prior to&#xD;
             the initiation of study medication.&#xD;
&#xD;
          7. Treatment with chemotherapy for the treatment of multiple myeloma or any&#xD;
             investigational agent within 6 weeks of study entry.&#xD;
&#xD;
          8. History of allergy to NSAIDs or aspirin-induced asthma.&#xD;
&#xD;
          9. Pregnancy or currently breast feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>February 16, 2006</study_first_submitted>
  <study_first_submitted_qc>February 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2006</study_first_posted>
  <last_update_submitted>May 8, 2014</last_update_submitted>
  <last_update_submitted_qc>May 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Relapsed Multiple Myeloma</keyword>
  <keyword>Refractory Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etodolac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

